See more : APT Satellite Holdings Limited (ASEJF) Income Statement Analysis – Financial Results
Complete financial analysis of SELLAS Life Sciences Group, Inc. (SLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SELLAS Life Sciences Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nilörngruppen AB (NIL-B.ST) Income Statement Analysis – Financial Results
- Club De Futbol Intercity Sad (CITY.MC) Income Statement Analysis – Financial Results
- Ether Capital Corporation (ETHC.NE) Income Statement Analysis – Financial Results
- TQR Public Company Limited (TQR.BK) Income Statement Analysis – Financial Results
- Ningbo Haitian Precision Machinery Co.,Ltd. (601882.SS) Income Statement Analysis – Financial Results
SELLAS Life Sciences Group, Inc. (SLS)
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 1.00M | 7.60M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.32M | 2.49M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 355.00K | 1.40M | 520.00K | 0.00 | 20.79M | 0.00 | 0.00 | 0.00 | 11.41M | 0.00 |
Gross Profit | 0.00 | 900.00K | 7.40M | 1.90M | 0.00 | 0.00 | 0.00 | -3.00K | -355.00K | 7.92M | 1.97M | 2.04M | -20.79M | 0.00 | 0.00 | 0.00 | -11.41M | 0.00 |
Gross Profit Ratio | 0.00% | 90.00% | 97.37% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.94% | 79.09% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 24.01M | 30.27M | 21.37M | 9.28M | 7.29M | 18.32M | 6.07M | 19.86M | 23.61M | 28.35M | 21.08M | 14.61M | 11.54M | 7.87M | 8.89M | 7.05M | 6.75M | 1.30M |
General & Administrative | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 6.86M | 8.75M | 8.63M | 4.87M | 3.74M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.39M | 0.00 | 0.00 | 2.63M | 931.00K | 0.00 |
SG&A | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 9.25M | 8.75M | 8.63M | 7.50M | 4.67M | 633.00K |
Other Expenses | 0.00 | 10.00M | 5.70M | 0.00 | 0.00 | -3.03M | 0.00 | 0.00 | 509.00K | 170.00K | 37.00K | -13.18M | 9.25M | 0.00 | 0.00 | 7.50M | 0.00 | 0.00 |
Operating Expenses | 37.87M | 42.85M | 32.69M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 60.14M | 35.81M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
Cost & Expenses | 37.87M | 42.95M | 32.89M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 61.54M | 36.33M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
Interest Income | 525.00K | 317.00K | 6.00K | 26.00K | 118.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180.00K | 448.00K | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 118.00K | 266.00K | 462.00K | 3.51M | 760.00K | 1.11M | 807.00K | 33.00K | 0.00 | 5.00K | -5.00K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 37.87M | 457.00K | 1.27M | 377.00K | 17.21M | 22.04M | 3.00K | 3.00K | 355.00K | 440.00K | 452.00K | 49.00K | 163.00K | 172.00K | 162.00K | 131.00K | 36.00K | 0.00 |
EBITDA | 529.00K | -31.95M | -19.66M | -16.40M | 668.00K | 0.00 | -23.04M | -15.99M | -37.48M | -36.61M | 7.63M | -34.38M | -11.32M | -11.82M | -18.22M | -14.24M | -10.93M | -2.41M |
EBITDA Ratio | 0.00% | -4,228.20% | -390.08% | -888.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -733.32% | 306.71% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -37.87M | -41.95M | -25.29M | -16.98M | -20.04M | -31.09M | -23.04M | -31.87M | -34.22M | -52.22M | -33.84M | -21.20M | -20.79M | -16.63M | -17.52M | -14.55M | -11.41M | -2.41M |
Operating Income Ratio | 0.00% | -4,195.00% | -332.82% | -893.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -560.38% | -1,360.68% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 529.00K | 649.00K | 4.36M | 208.00K | 668.00K | 2.54M | -7.79M | 5.13M | -4.37M | 13.62M | -41.79M | -13.18M | 9.30M | 4.63M | -867.00K | 180.00K | 448.00K | 0.00 |
Income Before Tax | -37.34M | -41.30M | -20.94M | -16.77M | -19.37M | -29.05M | -23.50M | -10.86M | -38.59M | -36.61M | -75.63M | -34.38M | -11.49M | -11.99M | -18.39M | -14.37M | -10.97M | -2.41M |
Income Before Tax Ratio | 0.00% | -4,130.10% | -275.47% | -882.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,040.85% | -1,686.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -649.00K | -237.00K | -17.00K | -81.00K | -1.38M | 253.00K | 243.00K | 365.00K | -15.45M | 1.05M | -1.05M | -9.30M | -4.63M | 867.00K | 0.00 | 25.00K | 0.00 |
Net Income | -37.34M | -40.65M | -20.70M | -16.76M | -19.29M | -27.67M | -23.75M | -23.55M | -63.90M | -36.61M | -76.68M | -34.97M | -11.49M | -11.99M | -18.39M | -14.37M | -10.99M | -2.41M |
Net Income Ratio | 0.00% | -4,065.20% | -272.36% | -881.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,083.15% | -1,715.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
EPS Diluted | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
Weighted Avg Shares Out | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.17K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
Weighted Avg Shares Out (Dil) | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.18K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Source: https://incomestatements.info
Category: Stock Reports